Peptides TA-1, MOTS-c and Retatrutide as Adjunctive Therapy in Cancer: What You Need to Know

Peptides and Cancer: A New Frontier in Integrative Oncology

Cancer treatment is rapidly evolving beyond chemotherapy and radiation. Modern oncology increasingly recognises that immune function, metabolism and mitochondrial health are deeply interconnected.

Several naturally occurring peptides are attracting significant scientific interest because they appear capable of influencing these systems simultaneously.

Among the most promising are:

• Thymosin Alpha-1 (TA-1)

• MOTS-c

• Retatrutide

Rather than acting as conventional chemotherapy, these compounds appear to influence:

• Immune surveillance

• T-cell activity

• Tumour metabolism

• Mitochondrial function

• Inflammatory signalling

• The tumour microenvironment

Importantly, none of these agents are established cancer treatments, and current evidence ranges from laboratory studies to animal models, with varying levels of human clinical data. They should be viewed as investigational adjunctive therapies rather than replacements for standard oncology care.

Infographic: Three Peptides, Three Complementary Targets

Why Cancer is a Disease of Both Immunity and Metabolism

Cancer cells survive by altering several biological systems simultaneously.

Key pathways include:

• PD-1 / PD-L1 immune checkpoint signalling

• AMPK metabolism

• mTOR

• PI3K-AKT

• NFκB inflammation

• Mitochondrial dysfunction

• Oxidative stress

• Immune exhaustion

• Amino acid sensing

• Protein translation

Rather than targeting only one pathway, emerging peptide therapies may influence multiple hallmarks of cancer simultaneously.

TA-1 (Thymosin Alpha-1): Restoring Immune Surveillance

What is TA-1?

TA-1 is a naturally occurring peptide produced within the thymus.

Its primary role is regulation of:

• T-cell maturation

• Dendritic cell activation

• NK cell activity

• Cytotoxic CD8+ T cells

• Innate immunity

Unlike chemotherapy, TA-1 primarily works by helping the immune system recognise abnormal cells more effectively.

Proposed Anti-Cancer Mechanisms

Enhanced Cytotoxic T Cell Function

TA-1 increases activation of:

• CD8 T cells

• NK cells

• Dendritic cells

leading to improved tumour recognition.

Reduction of Immune Exhaustion

Several studies suggest TA-1 helps restore exhausted T cells, improving immune responsiveness.

PD-1 Pathway

Current evidence suggests TA-1 does not directly inhibit PD-1 or PD-L1 in the way checkpoint inhibitor drugs do. Instead, it appears to:

• enhance T-cell activation,

• improve antigen presentation,

• increase interferon signalling,

which may complement checkpoint inhibitor therapies in some settings.

Additional Pathways

TA-1 has been associated with effects on:

• Toll-like receptor signalling

• NFκB

• Interferon pathways

• IL-2 production

• Th1 immune responses

Educational Infographic: TA-1 Immune Activation

MOTS-c: The Mitochondrial Peptide Changing Cancer Research

Perhaps the most exciting peptide currently being investigated is MOTS-c, a mitochondrial-derived peptide encoded within mitochondrial DNA.

Unlike most signalling peptides, MOTS-c acts as a master regulator of cellular energy metabolism.

Why MOTS-c Matters

Healthy cells require:

• efficient mitochondria

• balanced metabolism

• AMPK signalling

• protein quality control

Cancer progressively disrupts each of these systems.

Interestingly,

MOTS-c concentrations appear reduced in several cancers, and lower circulating levels have been associated with poorer prognosis in observational studies. While this association is compelling, it does not yet establish causation, and additional human studies are needed.

Major Metabolic Pathways Influenced by MOTS-c

MOTS-c activates:

• AMPK

• Mitochondrial biogenesis

• Fatty acid oxidation

• Insulin sensitivity

• Glucose utilisation

• Cellular stress responses

while suppressing excessive anabolic signalling.

The Fascinating LARS1–USP7 Discovery

One of the most important recent discoveries involves LARS1.

What is LARS1?

Leucyl-tRNA synthetase 1 (LARS1) is:

• an amino acid sensor

• regulator of protein synthesis

• upstream activator of mTOR signalling

Many cancers exploit LARS1 to sustain rapid growth.

USP7

USP7 is a deubiquitinase enzyme that stabilises many proteins involved in cancer biology. Among its functions, USP7 can stabilise proteins that support tumour cell survival, and its activity has made it a therapeutic target of interest in oncology research.

How MOTS-c Interacts with LARS1

Elegant preclinical research in ovarian cancer models suggests that MOTS-c:

• binds directly to LARS1,

• competes with USP7 for LARS1 binding,

• promotes LARS1 ubiquitination,

• accelerates LARS1 degradation,

• suppresses downstream proliferative signalling.

This represents a novel mechanism linking mitochondrial signalling to protein homeostasis and tumour growth.

Ovarian Cancer Research Summary

Educational Infographic: MOTS-c–USP7–LARS1 Pathway

Does MOTS-c Cause Cancer?

Current evidence does not demonstrate that MOTS-c promotes tumour growth.

In contrast, published preclinical ovarian cancer studies demonstrate:

• inhibition of tumour proliferation,

• reduced migration,

• increased apoptosis,

• suppression of tumour growth in vivo.

Theoretical Concern

Some peptide references have listed active cancer as a theoretical contraindication because AMPK signalling can influence metabolism in rapidly dividing cells.

Importantly:

• this concern is theoretical,

• it has not been demonstrated experimentally for MOTS-c,

• current laboratory evidence points toward anti-tumour rather than tumour-promoting activity in the models studied.

Likewise, broader concerns that peptides which stimulate angiogenesis or telomere maintenance could theoretically benefit cancer cells apply to certain peptide classes in general and are not specific findings for MOTS-c.

Retatrutide: More Than a Weight Loss Drug?

Retatrutide is a next-generation triple agonist targeting:

• GLP-1 receptor

• GIP receptor

• Glucagon receptor

Although initially developed for obesity and metabolic disease, exciting preclinical work suggests it may exert anti-tumour effects beyond weight reduction.

Proposed Anti-Tumour Mechanisms

Recent pancreatic cancer models demonstrated that retatrutide produced:

• marked tumour suppression,

• extensive immune activation,

• durable anti-tumour effects,

• benefits that persisted even after weight regain following treatment withdrawal.

This suggests that anti-cancer activity may be driven by immune reprogramming rather than metabolic changes alone.

Immune Pathways Activated

Research has identified activation of:

• TNFα signalling via NFκB

• Interferon α response

• Interferon γ response

• IL-2/STAT5 signalling

• Inflammatory response pathways

• Cytotoxic immune activation

These are immune signatures that overlap with those seen following successful checkpoint inhibitor therapy.

Retatrutide and PD-1

Importantly:

Current evidence does not show that retatrutide directly blocks the PD-1 receptor.

Instead, researchers propose that it may generate an immune landscape resembling that achieved with PD-1 blockade by promoting pro-inflammatory, anti-tumour immune activation within the tumour microenvironment.

In preclinical pancreatic cancer studies, low-dose retatrutide produced anti-tumour effects that were reported to be broadly comparable with anti-PD-1 immunotherapy in that model. These findings are hypothesis-generating and require validation in human clinical trials before conclusions about efficacy or mechanism can be drawn.

Educational Infographic: Retatrutide Immune Reprogramming

Putting the Three Peptides Together

Together they illustrate the emerging concept that effective adjunctive cancer strategies may need to address:

• metabolism,

• mitochondrial function,

• immune exhaustion,

• inflammatory signalling,

• tumour microenvironment,

• immune surveillance.

Clinical Perspective

These peptides represent an exciting area of translational research, but important limitations remain:

• Most mechanistic evidence comes from cell culture and animal studies.

• Human oncology data are limited, especially for MOTS-c and retatrutide as adjunctive cancer therapies.

• None should be considered replacements for surgery, chemotherapy, radiotherapy, immunotherapy, or other evidence-based cancer treatments.

• Any off-label or investigational use should occur under the supervision of appropriately qualified clinicians within a comprehensive cancer care plan.

Why Specialist Medical Supervision Matters

Because peptide therapies may interact with:

• immunotherapy,

• chemotherapy,

• endocrine therapy,

• targeted therapies,

• nutritional interventions,

patients should be managed by a qualified integrative and functional medicine doctor experienced in oncology, peptide therapeutics, metabolic medicine, and personalised treatment planning.

An evidence-informed approach can help integrate conventional cancer care with supportive therapies while carefully monitoring safety, potential interactions, and clinical outcomes.

About Omics Longevity

At Omics Longevity, we provide personalised integrative and functional medicine consultations focused on metabolic health, longevity, precision nutrition, peptide therapies, and evidence-informed supportive cancer care.

Website: www.OmicsLongevity.com.au

Phone: 0477 522 993

Book a consultation to discuss how personalised metabolic, nutritional, mitochondrial, and immune optimisation strategies may complement your overall health plan.

Key Takeaways

• TA-1 primarily supports immune surveillance and T-cell function rather than directly inhibiting PD-1.

• MOTS-c is a mitochondrial peptide that activates AMPK and, in preclinical ovarian cancer models, competes with USP7 for LARS1 binding, promoting LARS1 degradation, cell-cycle arrest, apoptosis, and tumour suppression without observed systemic toxicity.

• Reduced circulating MOTS-c levels have been associated with poorer outcomes in some cancers, although the clinical significance remains under investigation.

• Retatrutide has shown intriguing preclinical anti-tumour activity driven by immune reprogramming, with activation of TNFα/NFκB, interferon, and IL-2/STAT5 pathways. Its effects resemble aspects of PD-1 checkpoint blockade through immune activation rather than direct PD-1 inhibition.

• These findings are promising but remain largely preclinical, highlighting the need for well-designed human clinical trials before routine use in cancer care.